Statin-associated adverse cognitive effects: Survey results from 171 patients

Pharmacotherapy

Volumn 29, Issue 7, 2009, Pages 800-811

  Evans, Marcella A ^a,c   Golomb, Beatrice A ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitor; ADR; Adverse drug reaction; Cholesterol; Cognition; HMG CoA reductase inhibitor; Memory; Statin

Indexed keywords

ATORVASTATIN; CERIVASTATIN; EZETIMIBE; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ASSESSMENT; COGNITIVE DEFECT; CONVALESCENCE; DEMENTIA; DEMOGRAPHY; DISEASE COURSE; DRUG EFFECT; DRUG POTENCY; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MUSCLE DISEASE; NEUROPATHY; QUALITY OF LIFE; SELF REPORT; SIDE EFFECT; TRANSIENT GLOBAL AMNESIA; TREATMENT RESPONSE; VISUAL ANALOG SCALE; VULNERABLE POPULATION; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEMORY DISORDERS; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; TIME FACTORS;

EID: 67650805429     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.7.800     Document Type: Article

References (84)

1. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215-2220 (Pubitemid 34441937)
2. Temple RJ, Himmel MH. Safety of newly approved drugs: implications for prescribing. JAMA 2002;287:2273-2275 (Pubitemid 34441944)
3. Solomon DH, Avorn J. Coxibs, science, and the public trust. Arch Intern Med 2005;165:158-160
4. Graham GK. Postmarketing surveillance and black box warnings. JAMA 2002;288:955-959
5. McNeil JJ, Grabsch EA, McDonald MM. Postmarketing surveillance: strengths and limitations-the flucloxacillindicloxacillin story. Med J Aust 1999;170:270-273 (Pubitemid 29129345)
6. Arnaiz JA, Carne X, Riba N, Codina C, Ribas J, Trilla A. The use of evidence in pharmacovigilance: case reports as the reference source for drug withdrawals. Eur J Clin Pharmacol 2001;57:89-91 (Pubitemid 32391420)
7. Kennedy DL, Goldman SA. Monitoring for adverse drug events. Am Fam Physician 1997;56:1718-1721
8. van Grootheest K, de Graaf L, de Jong-van den Berg LT. Consumer adverse drug reaction reporting: a new step in pharmacovigilance? Drug Saf 2003;26:211-217
9. Golomb BA, McGraw JJ, Evans MA, Dimsdale JE. Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance. Drug Saf 2007;30:669-675 (Pubitemid 47295826)
10. Medawar C, Herxheimer A. A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behavior. Int J Risk Safety Med 2003-2004;16:5-19 (Pubitemid 37475764)
11. Lepor NE, Vogel RE. Summary of the third report of the national cholesterol education program adult treatment panel III. Rev Cardiovasc Med 2001;2:160-165
12. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the national cholesterol education program ault treatment panel III guidelines. Arterioscler Thromb Vasc Biol 2004;24:e149-61
13. Scott RS, Lintott CJ, Wilson MJ. Simvastatin and side effects. N Z Med J 1991;104:493-495
14. Wierzbicki AS, Lumb PJ, Semra Y, Chik G, Christ ER, Crook MA. Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias. QJM 1999;92:387-394 (Pubitemid 29346883)
15. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581-585
16. Antons KA, Williams CD, Baker SK, Phillips PS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006;119:400-409
17. Phillips PS. How common is rhabdomyolysis in patients receiving lipid-lowering therapy? Nat Clin Pract Cardiovasc Med 2005;2:130-131
18. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statinrelated adverse events: a meta-analysis. Clin Ther 2006;28: 26-35
19. McClure DL, Valuck RJ, Glanz M, Hokanson JE. Systematic review and meta-analysis of clinically relevant adverse events from HMG-CoA reductase inhibitor trials worldwide from 1982 to present. Pharmacoepidemiol Drug Saf 2007;16:132-143
20. Padala KP, Padala PR, Potter JF. Simvastatin-induced decline in cognition. Ann Pharmacother 2006;40:1880-1883
21. Galatti L, Polimeni G, Salvo F, Romani M, Sessa A, Spina E. Short-term memory loss associated with rosuvastatin. Pharmacotherapy 2006;26:1190-1192 (Pubitemid 44167829)
22. Tatley M, Savage R. Psychiatric adverse reactions with statins, fibrates and ezetimibe: implications for the use of lipidlowering agents. Drug Saf 2007;30:195-201 (Pubitemid 46425633)
23. King DS, Jones DW, Wofford MR, Harkins K, Harrell K, Kelley KW. Cognitive impairment associated with atorvastatin [abstract]. Pharmacotherapy 2001;21:371
24. King DS, Wilburn AJ, Wofford MR, Harrell TK, Lindley BJ, Jones DW. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy 2003;23:1663-1667 (Pubitemid 37485319)
25. Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associated memory loss. Pharmacotherapy 2001;21:767-769
26. Wagstaff LR, Mitton MW, McLendon Arvik B, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003;23:871-880 (Pubitemid 36875671)
27. Muldoon MF, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med 2000;108:538-546 (Pubitemid 30249031)
28. Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med 2004;117:823-829 (Pubitemid 39602790)
29. Criqui MH, Golomb BA. Low and lowered cholesterol and total mortality. J Am Coll Cardiol 2004;44:1009-1010 (Pubitemid 39165134)
30. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245
31. Kelly WN, Arellano FM, Barnes J, et al. Guidelines for submitting adverse event reports for publication. Drug Saf 2007;30:367-373 (Pubitemid 46740334)
32. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-1389 (Pubitemid 24365311)
33. The Long-Term Intervention with Pravastatin in Ischaemic Disease (Lipid) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels [see comments]. N Engl J Med 1998;339:1349-1357
34. Shepherd J, Blauw GJ, Murphy MB, et al, for the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-1630 (Pubitemid 35379733)
35. Downs JR, Clearfield M, Tyroler HA, et al. Air Force/Texas coronary atherosclerosis prevention study (AFCAPS/ TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol 2001;87:1074-1079 (Pubitemid 32710322)
36. Larner AJ. Transient global amnesia in the district general hospital. Int J Clin Pract 2007;61:255-258 (Pubitemid 46271287)
37. Shekhar R. Transient global amnesia: a review. Int J Clin Pract 2008;62:939-942
38. IMS Health. Commonly requested therapeutic class and product information (update February 2006). Available from http://www1.imshealth.com/ims/portal/ front/articleC/0,2777,65 99-18731-77056778,00.html. Accessed April 17, 2009
39. IMS Health. National prescription audit plus™. U.S. top ten products by prescriptions. Available from http://www.imshealth .com/public/structure/dispcontent/1,2779,1343-1343-144004,00.html. Accessed April 19, 2002
40. IMS Health. Lipitor leads the way in 2003. Available from http://www.ims-global.com/insight/news-story /0403/news- story-040316.htm. Accessed May 23, 2005
41. IMS Health. IMS global insights-IMS retail drug Monitor December 2007. Available from http://www.imshealth.com /web/content/0,3148,64576068-63872702- 70260998-8374658 5,00.html. Accessed May 2, 2008
42. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997;80:106-107
43. Miller AE, Hansen LB, Saseen JJ. Switching statin therapy using a pharmacist-managed therapeutic conversion program versus usual care conversion among indigent patients. Pharmacotherapy 2008;28:553-561 (Pubitemid 351620023)
44. Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, Sundaresen P. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 2000;68:391-400 (Pubitemid 30803528)
45. Ose L, Luurila O, Eriksson J, Olsson A, Lithell H, Widgren B, for the Cerivastatin Study Group. Efficacy and safety of cerivastatin, 0.2 mg and 0.4 mg, in patients with primary hypercholesterolaemia: a multinational, randomised, doubleblind study. Curr Med Res Opin 1999;15:228-240 (Pubitemid 29481481)
46. Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006;34:153-162 (Pubitemid 44167798)
47. Golomb BA, Dimsdale JE, White HL, Ritchie JB, Criqui MH. Reductions in blood pressure with statins: results from the UCSD statin study, a randomized trial. Arch Intern Med 2008;168:721-727 (Pubitemid 351563955)
48. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008;8:373-418
49. Link E, Parish S, Armitage J, et al, for The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy: a genomewide study. N Engl J Med 2008;359:789-799
50. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TEXCAPS, the Air Force/Texas coronary atherosclerosis prevention study [see comments]. JAMA 1998;279:1615-1622
51. The Long-Term Intervention with Pravastatin in Ischaemic Disease (Lipid) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357
52. Amarenco P, Bogousslavsky J, Callahan A III, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-559 (Pubitemid 44202151)
53. Golomb BA, Criqui MH, White H, Dimsdale JE. Conceptual foundations of the UCSD statin study: a randomized controlled trial assessing the impact of statins on cognition, behavior, and biochemistry. Arch Intern Med 2004;164:153-162 (Pubitemid 38140401)
54. Golomb BA, Criqui MH, White HL, Dimsdale JE. The UCSD statin study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes. Control Clin Trials 2004;25:178-202 (Pubitemid 38328758)
55. Boitier E, Degoul F, Desguerre I, et al. A case of mitochondrial encephalomyopathy associated with a muscle coenzyme Q10 deficiency. J Neurol Sci 1998;156:41-46 (Pubitemid 28141037)
56. Sobreira C, Hirano M, Shanske S, et al. Mitochondrial encephalomyopathy with coenzyme Q10 deficiency. Neurology 1997;48:1238-1243 (Pubitemid 27240541)
57. Goda S, Hamada T, Ishimoto S, Kobayashi T, Goto I, Kuroiwa Y. Clinical Improvement after administration of coenzyme Q10 in a patient with mitochondrial encephalomyopathy. J Neurol 1987;234:62-63
58. Sparks DL, Connor DJ, Sabbagh MN, Petersen RB, Lopez J
59. Browne P. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's disease cholesterol-lowering treatment (ADCLT) trial. Acta Neurol Scand Suppl 2006;185:3-7 (Pubitemid 44015218)
60. Vrecer M, Turk S, Drinovec J, Mrhar A. Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke: meta-analysis of randomized trials. Int J Clin Pharmacol Ther 2003;41:567-577 (Pubitemid 37527563)
61. Collins R, Armitage J, Parish S, Sleight P, Peto R. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebocontrolled trial. Lancet 2002;360:7-22 (Pubitemid 34756487)
62. Bruckert E, Simonetta C, Giral P, for the CREOLE Study Team. Compliance with fluvastatin treatment characterization of the noncompliant population within a population of 3845 patients with hyperlipidemia. J Clin Epidemiol 1999;52: 589-594 (Pubitemid 29284819)
63. Stilley CS, Sereika S, Muldoon MF, Ryan CM, Dunbar-Jacob J. Psychological and cognitive function: predictors of adherence with cholesterol lowering treatment. Ann Behav Med 2004;27:117-124 (Pubitemid 38364891)
64. Golomb BA, Dimsdale JE, White HL, Criqui MH. Do low dose statins affect cognition? Results of the UCSD statin study [abstract]. Circulation 2006;114(18 suppl):II-289
65. Sparks DL, Sabbagh M, Connor D, et al. Statin therapy in Alzheimer's disease. Acta Neurol Scand Suppl 2006;185:78-86
66. Simons M, Schwarzler F, Lutjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, doubleblind trial. Ann Neurol 2002;52:346-350 (Pubitemid 35001502)
67. Hajjar I, Schumpert J, Hirth V, Wieland D, Eleazer GP. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci 2002;57:M414-18 (Pubitemid 34733805)
68. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000;356:1627-1631
69. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3- hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57:1439-1443 (Pubitemid 30769120)
70. Li G, Larson EB, Sonnen JA, et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 2007;69:878-885 (Pubitemid 47329587)
71. Golomb BA, Jaworski BA. Statins and dementia. Arch Neurol 2001;58:1169-1170
72. Golomb BA, Evans MA. Re: statin therapy is associated with reduced neuropathologic changes of Alzheimer disease [correspondence]. Neurology 2008;70:2349; author reply 2350
73. Cholerton B, Gleason CE, Baker LD, Asthana S. Estrogen and Alzheimer's disease: the story so far. Drugs Aging 2002;19: 405-427 (Pubitemid 34941132)
74. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the women's health initiative memory study-a randomized controlled trial. JAMA 2003;289:2663-2672 (Pubitemid 37430137)
75. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the women's health initiative memory study-a randomized controlled trial. JAMA 2003;289:2651-2662 (Pubitemid 37430136)
76. Adverse Drug Reactions Advisory Committee (ADRAC). Statins and peripheral neuropathy. Aust Adverse Drug React Bull 2005;24(2):6. Available from http://www.tga. health.gov.au/ adr/aadrb/aadr0504.htm
77. Chong PH, Boskovich A, Stevkovic N, Bartt RE. Statinassociated peripheral neuropathy: review of the literature. Pharmacotherapy 2004;24:1194-1203 (Pubitemid 39128843)
78. Phan T, McLeod JG, Pollard JD, Peiris O, Rohan A, Halpern JP. Peripheral neuropathy associated with simvastatin. J Neurol Neurosurg Psychiatry 1995;58:625-628
79. Griffin GC, Parkinson RW, Woolley BH. Report every adverse drug reaction! We're all in this together. Postgrad Med 1997;101:13-16 (Pubitemid 27187553)
80. Jessen F, Feyen L, Freymann K, et al. Volume reduction of the entorhinal cortex in subjective memory impairment. Neurobiol Aging 2006;27:1751-1756
81. Wang PJ, Saykin AJ, Flashman LA, et al. Regionally specific atrophy of the corpus callosum in AD, MCI and cognitive complaints. Neurobiol Aging 2006;27:1613-1617 (Pubitemid 44344845)
82. Geerlings MI, Jonker C, Bouter LM, Ader HJ, Schmand B. Association between memory complaints and incident Alzheimer's disease in elderly people with normal baseline cognition. Am J Psychiatry 1999;156:531-537 (Pubitemid 29162972)
83. Jorm AF, Masaki KH, Petrovitch H, Ross GW, White LR. Cognitive deficits 3 to 6 years before dementia onset in a population sample: the Honolulu-Asia aging study. J Am Geriatr Soc 2005;53:452-455 (Pubitemid 41623524)
84. Wang L, van Belle G, Crane PK, et al. Subjective memory deterioration and future dementia in people aged 65 and older. J Am Geriatr Soc 2004;52:2045-2051 (Pubitemid 41725021)